Weighted Average Number of Shares Outstanding, Basic of ENANTA PHARMACEUTICALS INC from 30 Sep 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
ENANTA PHARMACEUTICALS INC quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Sep 2011 to 31 Dec 2025.
  • ENANTA PHARMACEUTICALS INC Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 28,748,000, a 35% increase year-over-year.
  • ENANTA PHARMACEUTICALS INC annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 21,336,000, a 0.85% increase from 2024.
  • ENANTA PHARMACEUTICALS INC annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 21,157,000, a 0.9% increase from 2023.
  • ENANTA PHARMACEUTICALS INC annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 20,969,000, a 1.8% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

ENANTA PHARMACEUTICALS INC Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 28,748,000 +7,510,000 +35% 01 Oct 2025 31 Dec 2025 10-Q 11 Feb 2026 2026 Q1
Q3 2025 21,336,000 +179,000 +0.85% 01 Jul 2025 30 Sep 2025 10-K 19 Nov 2025 2025 FY
Q2 2025 21,377,000 +197,000 +0.93% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q3
Q1 2025 21,355,000 +188,000 +0.89% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q2
Q4 2024 21,238,000 +150,000 +0.71% 01 Oct 2024 31 Dec 2024 10-Q 11 Feb 2026 2026 Q1
Q3 2024 21,157,000 +188,000 +0.9% 01 Jul 2024 30 Sep 2024 10-K 19 Nov 2025 2025 FY
Q2 2024 21,180,000 +126,000 +0.6% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q3
Q1 2024 21,167,000 +132,000 +0.63% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q2
Q4 2023 21,088,000 +272,000 +1.3% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2024 Q1
Q3 2023 20,969,000 +366,000 +1.8% 01 Jul 2023 30 Sep 2023 10-K 19 Nov 2025 2025 FY
Q2 2023 21,054,000 +344,000 +1.7% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q3
Q1 2023 21,035,000 +484,000 +2.4% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q2
Q4 2022 20,816,000 +428,000 +2.1% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2024 2024 Q1
Q3 2022 20,603,000 +432,000 +2.1% 01 Jul 2022 30 Sep 2022 10-K 27 Nov 2024 2024 FY
Q2 2022 20,710,000 +509,000 +2.5% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q3
Q1 2022 20,551,000 +380,000 +1.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q2
Q4 2021 20,388,000 +295,000 +1.5% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q1
Q3 2021 20,171,000 +231,000 +1.2% 01 Jul 2021 30 Sep 2021 10-K 22 Nov 2023 2023 FY
Q2 2021 20,201,000 +181,000 +0.9% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q3
Q1 2021 20,171,000 +249,000 +1.2% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q2
Q4 2020 20,093,000 +342,000 +1.7% 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q1
Q3 2020 19,940,000 +356,000 +1.8% 01 Jul 2020 30 Sep 2020 10-K 23 Nov 2022 2022 FY
Q2 2020 20,020,000 +347,000 +1.8% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q3
Q1 2020 19,922,000 +373,000 +1.9% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q2
Q4 2019 19,751,000 +325,000 +1.7% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q1
Q3 2019 19,584,000 +329,000 +1.7% 01 Jul 2019 30 Sep 2019 10-K 24 Nov 2021 2021 FY
Q2 2019 19,673,000 +370,000 +1.9% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q3
Q1 2019 19,549,000 +343,000 +1.8% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q2
Q4 2018 19,426,000 +296,000 +1.5% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q1
Q3 2018 19,255,000 +189,000 +0.99% 01 Jul 2018 30 Sep 2018 10-K 25 Nov 2020 2020 FY
Q2 2018 19,303,000 +222,000 +1.2% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q3
Q1 2018 19,206,000 +159,000 +0.84% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q2
Q4 2017 19,130,000 +92,000 +0.48% 01 Oct 2017 31 Dec 2017 10-Q 08 Feb 2019 2019 Q1
Q3 2017 19,066,000 +137,000 +0.72% 01 Jul 2017 30 Sep 2017 10-K 27 Nov 2019 2019 FY
Q2 2017 19,081,000 +98,000 +0.52% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q3
Q1 2017 19,047,000 +126,000 +0.67% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q2
Q4 2016 19,038,000 +262,000 +1.4% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018 2018 Q1
Q3 2016 18,929,000 +256,000 +1.4% 01 Jul 2016 30 Sep 2016 10-K 29 Nov 2018 2018 FY
Q2 2016 18,983,000 +285,896 +1.5% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q3
Q1 2016 18,921,000 +241,102 +1.3% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q2
Q4 2015 18,776,000 +172,933 +0.93% 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017 2017 Q1
Q3 2015 18,673,000 +318,000 +1.7% 01 Jul 2015 30 Sep 2015 10-K 11 Dec 2017 2017 FY
Q2 2015 18,697,104 +168,271 +0.91% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q3
Q1 2015 18,679,898 +326,270 +1.8% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q2
Q4 2014 18,603,067 +653,595 +3.6% 01 Oct 2014 31 Dec 2014 10-Q 09 Feb 2016 2016 Q1
Q3 2014 18,355,000 +8,566,961 +88% 01 Jul 2014 30 Sep 2014 10-K 09 Dec 2016 2016 FY
Q2 2014 18,528,833 +709,020 +4% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q3
Q1 2014 18,353,628 +16,161,158 +737% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q2
Q4 2013 17,949,472 +16,791,419 +1450% 01 Oct 2013 31 Dec 2013 10-Q 06 Feb 2015 2015 Q1
Q3 2013 9,788,039 01 Jul 2013 30 Sep 2013 10-K 11 Dec 2015 2015 FY
Q2 2013 17,819,813 +16,699,413 +1490% 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014 2014 Q3
Q1 2013 2,192,470 +1,104,219 +101% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q2
Q4 2012 1,158,053 01 Oct 2012 31 Dec 2012 10-Q 13 Feb 2014 2014 Q1
Q2 2012 1,120,400 01 Apr 2012 30 Jun 2012 10-Q 12 Aug 2013 2013 Q3
Q1 2012 1,088,251 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q2

ENANTA PHARMACEUTICALS INC Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 21,336,000 +179,000 +0.85% 01 Oct 2024 30 Sep 2025 10-K 19 Nov 2025 2025 FY
2024 21,157,000 +188,000 +0.9% 01 Oct 2023 30 Sep 2024 10-K 19 Nov 2025 2025 FY
2023 20,969,000 +366,000 +1.8% 01 Oct 2022 30 Sep 2023 10-K 19 Nov 2025 2025 FY
2022 20,603,000 +432,000 +2.1% 01 Oct 2021 30 Sep 2022 10-K 27 Nov 2024 2024 FY
2021 20,171,000 +231,000 +1.2% 01 Oct 2020 30 Sep 2021 10-K 22 Nov 2023 2023 FY
2020 19,940,000 +356,000 +1.8% 01 Oct 2019 30 Sep 2020 10-K 23 Nov 2022 2022 FY
2019 19,584,000 +329,000 +1.7% 01 Oct 2018 30 Sep 2019 10-K 24 Nov 2021 2021 FY
2018 19,255,000 +189,000 +0.99% 01 Oct 2017 30 Sep 2018 10-K 25 Nov 2020 2020 FY
2017 19,066,000 +137,000 +0.72% 01 Oct 2016 30 Sep 2017 10-K 27 Nov 2019 2019 FY
2016 18,929,000 +256,000 +1.4% 01 Oct 2015 30 Sep 2016 10-K 29 Nov 2018 2018 FY
2015 18,673,000 +318,000 +1.7% 01 Oct 2014 30 Sep 2015 10-K 11 Dec 2017 2017 FY
2014 18,355,000 +8,566,961 +88% 01 Oct 2013 30 Sep 2014 10-K 09 Dec 2016 2016 FY
2013 9,788,039 +8,699,255 +799% 01 Oct 2012 30 Sep 2013 10-K 11 Dec 2015 2015 FY
2012 1,088,784 -30,466 -2.7% 01 Oct 2011 30 Sep 2012 10-K 11 Dec 2014 2014 FY
2011 1,119,250 01 Oct 2010 30 Sep 2011 10-K 18 Dec 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.